On Thursday, Vigil Neuroscience Inc. VIGL released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease.Key takeaways from the Phase 1 clinical trial of VG-3927 include:Demonstrated a favorable safety and tolerability profile across all cohorts, including the elderly cohort.All related adverse events were mild or moderate in severity and self-resolving without drug discontinuations. No serious AEs were reported.Highly brain penetrant with a favorable and ...

- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) - - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement – - Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology - WATERTOWN, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vigi ...

– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for 2Q 2025 – – Company well-positioned for continued operational progress in 2025 – WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodege ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------------------|------------------------------------------------| | | | | For the t ...

Exhibit 99.1 Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer's Disease on track for first quarter of 2025 - WATERTOWN, Mass. – November 7, 2024 – Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the tre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-41200 VIGIL NEUROSCIENCE, INC. (Exact name of Registrant as specified in its Charter) Del ...

Exhibit 99.1 Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update - Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., August 13, 2024 (G ...

VG-3927 Clinical Trial Progress - VG-3927 demonstrates potential as a differentiated approach to treating Alzheimer's disease (AD) with improved safety and efficacy, addressing multiple aspects of AD pathophysiology [1] - The ongoing Phase 1 trial has enrolled 80 healthy volunteers, with 60 receiving VG-3927 across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts as of June 30, 2024 [1] - Interim data shows VG-3927 achieved a robust decrease in sTREM2 in cerebrospinal fluid (CSF), demonstrating clinical proof-of-target engagement [3] - VG-3927's safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile supports its continued development as a potential once-daily oral therapy for AD [3][8] - The company plans to report complete Phase 1 data, including data from the AD patient cohort, in Q1 2025 [3][9] VG-3927 Mechanism and Biomarker Data - VG-3927 acts as a TREM2 agonist, converting microglia into a neuroprotective state, supported by preclinical and clinical data [3] - VG-3927 showed a predictable PK profile supportive of once-daily dosing and a sustained decrease in sTREM2 in CSF across SAD and MAD cohorts [5] - Repeat dosing of VG-3927 increased osteopontin/secreted phosphoprotein 1 (SPP1), a biomarker associated with neuroprotective microglia [5] - No effect on soluble Colony Stimulating Factor 1 Receptor (sCSF1R), a microglial trophic factor, has been observed to date [5] Company Strategy and Pipeline - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring microglia function [6] - The company's lead candidate, iluzanebart, is a monoclonal antibody targeting TREM2 for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) [6] - VG-3927, a small molecule TREM2 agonist, is being developed for AD and other neurodegenerative diseases associated with microglial dysfunction [6] Upcoming Presentations and Data Releases - Vigil plans to present new preclinical and clinical data from the VG-3927 SAD cohorts at the 2024 Alzheimer's Association International Conference (AAIC) [7][8] - The company has commenced screening for an AD patient cohort in the Phase 1 trial to explore biomarker responses after a single dose of VG-3927 [9]

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations highlighting its oral small molecule VG-3927 at the 2024 Alzheimer's Association International Conference (AAIC) taking place on July 28-August 1, 2024 in Philadelphia, Pennsylvania and virtually. Title: Pharmacological and functi ...

Details of the oral presentation are as follows: Details of the poster presentations are as follows: Title: Pharmacological and functional characterization of the first small molecule TREM2 agonist, VG-3927, for the treatment of Alzheimer's disease Presented by: Borislav Dejanovic, Ph.D., Vigil Neuroscience Date and Time: Sunday, July 28, 2024, 8:00 AM – 4:15 PM EDT (Poster location Sunday-77) About Vigil Neuroscience Vigil Neuroscience routinely posts information that may be important to investors in the ' ...